曲氟尿苷替匹嘧啶在转移性结直肠癌中的应用进展  

Application progress of Trifluridine/Tipiracil in metastatic colorectal cancer

作　　者：张玉琪 林思祥 李艳如 唐思杰 ZHANG Yuqi;LIN Sixiang;LI Yanru;TANG Sijie(The Second Clinical Medical College of Binzhou Medical University,Shandong,Yantai 264100,China;Cancer Center,Affiliated Hospital of Binzhou Medical University in Yantai City,Shandong,Yantai 264100,China)

机构地区：[1]滨州医学院第二临床医学院,山东烟台264100 [2]滨州医学院烟台附属医院肿瘤中心,山东烟台264100

出　　处：《中国医药科学》2025年第5期33-36,共4页China Medicine And Pharmacy

基　　金：山东省烟台市科技创新发展计划(2020MSGY084)。

摘　　要：结直肠癌(CRC)是全球常见的恶性肿瘤,早期症状不明显、诊断困难,而转移性结直肠癌(mCRC)患者预后较差。新型化疗药物曲氟尿苷替匹嘧啶(TAS-102)是一种氟尿嘧啶类药物,具有抑制肿瘤生长和血管生成的作用,能显著延长mCRC患者的中位总生存期(mOS)和中位无进展生存期(mFPS)。TAS-102的不良反应可控,已经被多个权威指南推荐为晚期三线CRC的标准化疗药物。此外,TAS-102联合多种药物尤其是靶向药物贝伐珠单抗治疗使mCRC患者有较好获益,成为治疗mCRC的新选择。本文阐述了TAS-102的作用机制及其在mCRC的临床应用,并对TAS-102新的联合治疗方案进行展望。Colorectal cancer(CRC)is a common malignant tumor in the world,and its early symptoms are not obvious,and its diagnosis is difficult.However,patients with metastatic colorectal cancer(mCRC)have a poor prognosis.Trifluridine/Tipiracil(TAS-102),a new chemotherapy drug,is a fluorouracil drug,which can inhibit tumor growth and angiogenesis,and can significantly prolong the median overall survival(mOS)and median progression free survival(mFPS)of mCRC patients.The adverse reactions of TAS-102 can be controlled,and it has been recommended by many authoritative guidelines as the standard chemotherapy drug for advanced third-line colorectal cancer.In addition,TAS-102 combined with multiple drugs,especially the targeted drug bevacizumab,has benefited mCRC patients and become a new choice for the treatment of mCRC.The function mechanism of TAS-102 and its clinical application in mCRC is expounded,and the new combined treatment scheme of TAS-102 is looked forward in this paper.

关 键 词：曲氟尿苷替匹嘧啶 化疗 结直肠癌 氟尿嘧啶类 

分 类 号：R735.34[医药卫生—肿瘤]